Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 5/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | EDNRA | P25101 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26330021 | 0.78 | ADRA1A (0.39) | ADRA1AADRA1DCHRM2CHRM1CHRM3 | |
| SCHEMBL23999683 | 0.78 | ATR (0.33) | — | |
| SCHEMBL26311886 | 0.77 | ADRA1A (0.61) | ADRA1AADRA1DCHRM2CHRM1CHRM3 | |
| SCHEMBL25820215 | 0.76 | HTR2A (0.40) | — | |
| SCHEMBL26330038 | 0.73 | ADRA1A (0.36) | ADRA1AADRA1DCHRM2CHRM1CHRM3 | |
| SCHEMBL26330023 | 0.73 | CCNT1 (0.36) | ADRA1AADRA1DCHRM2CHRM1CHRM3 | |
| SCHEMBL25831559 | 0.73 | ADRA1A (0.36) | ADRA1AADRA1DCHRM2CHRM1CHRM3 | |
| SCHEMBL25831546 | 0.72 | ADRA1A (0.35) | ADRA1AADRA1DCHRM2CHRM1CHRM3 | |
| SCHEMBL26330047 | 0.72 | ADRA1A (0.49) | ADRA1AADRA1DCHRM2CHRM1CHRM3 | |
| SCHEMBL24006324 | 0.71 | SIGMAR1 (0.41) | ADRA1ACHRM2CHRM1CHRM3ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | ADRA1A 3488/4885ADRA1D 3932/4885CHRM2 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.